Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
| Overview / Abstract: |
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized education is essential to accommodate early career providers, community oncologists, and advanced specialists. The ACHL AdaptEd® platform achieves this by expanding and contracting to accommodate different learning needs to achieve meaningful results. |
|
Expiration |
Dec 22, 2024 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.25 hours |
|
Accreditation |
ACCME, ACPE, AAPA, ANCC |
|
Presenters / Authors / Faculty |
Faiz Anwer, MD, FACP Surbhi Sidana, MD |
|
Sponsors / Supporters / Grant Providers |
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer. |
|
Keywords / Search Terms |
ACHL Multiple Myeloma, myeloma, relapsed/refractory, BCMA-directed therapies, GPRC5D, RRMM, RR/MM, targeted therapies, adaptive, personalized treatment, hematology, oncology, hematologist, oncologist, MM therapies, treatment, novel agents, agents, MOA, mechanisms of action, clinical evidence, adverse events, personalized learning, simulated cases, teclistamab, elranatamab, Pfizer, Janssen, Cleveland Clinic, CCF, ACPE, ANCC, AAPA Free CE CME |
|